Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Ironwood Pharmaceuticals, Inc.)"
Count: 42
Selected: 0
NCT IDTitle
NCT03226899A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
NCT05740007Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
NCT05362695A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects
NCT05188261A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers
NCT03931785A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
NCT03856970Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers
NCT03573908A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03561883Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
NCT03561090A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
NCT02837783A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT02637557A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
NCT02559206Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT02291679Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
NCT02289846Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
NCT02030925Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
NCT01712412Phase 2a Study of IW-9179 to Treat Functional Dyspepsia
NCT01107236Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction
NCT00938717Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT00730171An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
NCT00730015Trial of Linaclotide in Patients With Chronic Constipation
NCT00460811Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT00404001Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
NCT00402337Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation
NCT00306748Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
NCT00258193Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
NCT05760313A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
NCT05652205A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
NCT04166058Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
NCT04110145Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
NCT04026113Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
NCT02590432An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
NCT02559817A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
NCT02559570A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
NCT02270983Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
NCT02144376MRI and Microbiota Analysis in Constipation
NCT01880424A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT01805999Ispaghula and Colonic Water Content
NCT01642914Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
NCT00948818Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
NCT00765999An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
NCT00765882Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
NCT05796388A Study of Virtual Reality and Linaclotide for IBS-C